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To investigate whether organ transplantation was associated with a quantitative aberration in the concentrations of circulating DNA, we compared total plasma DNA concentrations in the transplant patients and the 10 healthy controls. The median DNA concentrations of the controls and the patients studied were 916.4 and 1336.3 genome-equivalents/mL, respectively. No significant difference was observed between these values (Mann-Whitney rank-sum test, P ϭ 0.076).
In this study, we have provided a quantitative estimation of the proportions of plasma cell-free DNA originating from different nonhematopoietic tissues, namely, the heart, the liver, and the kidneys. These nonhematopoietic cells accounted for only a minority of the free circulating DNA, agreeing with our previous findings that the hematopoietic system is the predominant origin of plasma cell-free DNA (2 ) .
Although our previous study revealed the presence of donor-specific DNA in the plasma of kidney and liver transplant recipients (6 ), the present work provides the first quantitative study of donor-specific DNA sequences in the plasma of patients receiving solid organ transplants. The quantitative information in this report provides normative values for clinically stable posttransplantation patients with no evidence of graft rejection or other pathologies. Because plasma DNA has been associated with cell death (7 ), plasma donor DNA may be released as a result of graft rejection or other sources of tissue damage in the transplanted organ, such as graft infection and neoplastic involvement of the graft. This suggests the theoretical possibility that the concentration of donor DNA in the recipient's plasma may be a marker for these processes. Of relevance is the recent demonstration that urinary cell-free DNA is increased in patients with renal graft rejection (8, 9 ) . In this regard, it would be interesting to obtain quantitative data for serial samples from patients receiving solid organ transplants, especially those who are suffering from graft rejection episodes. Wilson disease (WD) is an autosomal recessive disorder of copper transport resulting from the defective function of a copper-transporting ATPase (ATP7B) (1) (2) (3) . More than 200 disease-causing mutations have been identified (4 ). In the Sardinian population, WD has an incidence of ϳ1 in 7000 live births (5 ). Using single-strand conformation polymorphism (SSCP) and sequencing methods for mutation analysis, we have characterized 92% of the chromosomes analyzed and identified 16 different WD-causing mutations, 6 of which (Ϫ441/Ϫ427del, 213-214delAT, 1512-1513insT, R778W, 2463delC, and V1146M) are relatively common and account for 85% of chromosomes (6 ) . On the basis of these data, we developed a reverse dot-blot (RDB) method as a practical solution to mutation screening in this population.
DNA samples from Sardinian WD patients carrying different combinations of the most common mutations (Ϫ441/Ϫ427del, 2463delC, V1146M, 213-214delAT, 1512-1513insT, and R778W) were used as controls. Our aim was to obtain the same PCR conditions for all six pairs of primers that were used to amplify the regions containing the six most common mutations. We therefore designed primers with an identical melting temperatures and tested their specificity first in single and then in multiplex PCRs. We also wanted to obtain relatively equal yields for all PCR products to obtain comparable signals using the RDB method. We therefore tested different concentrations for each pair of primers and finally established primer concentrations that allowed us to obtain approximately equal yields for the six PCR products. After repeated experiments and adjustment of the primer lengths and concentrations, we finally obtained six pairs of primers that permitted specific amplification using an annealing temperature of 60°C (Fig. 1A and Table 1 ). The PCR products ranged from 93 to 430 bp in size (Fig. 1A and Table 1 ). The experiments were performed in 25 L of 1ϫ buffer containing 1.5 mM MgCl 2, 0.2 mM deoxynucleotide triphosphates, 0.05 mM biotin 16-dUTP, and 1 U of Taq polymerase. Primers were used at the concentrations described in Table 1 . The reactions were performed on 100 ng of genomic DNA in a Gene-Amp 2400 (Perkin-Elmer) with an initial denaturation of 5 min at 94°C, followed by 30 cycles of denaturation for 30 s at 94°C and annealing for 30 s at 60°C, with extension for 1 min at 72°C for each cycle and a final extension of 10 min at 72°C. After amplification, 5 L of the PCR mixture was analyzed on a 2% agarose gel.
The criteria used to set up the RDB assay were (a) a stringent hybridization to differentiate between oligonucleotides differing by only one base pair and (b) the same hybridization conditions for all wild-type/mutant (WT/ MT) oligonucleotide pairs. Different oligonucleotides were synthesized and covalently attached to membranes via an amino linker. By varying the length and by experimentally testing the oligonucleotides, we obtained uniform hybridization conditions for all WT and MT probes at 53°C. The oligonucleotide concentrations were the second variable investigated. They were tested in the same set of experiments using different concentrations for each probe. The WT oligonucleotide probes, which have a strong signal when hybridized to the WT PCR products and no signal when hybridized to the MT PCR products, were chosen as the WT probe; those that gave no signal when hybridized to WT products and a strong signal when hybridized to MT PCR products were chosen as the MT probes (Fig. 1B) . This was repeated for all six mutations. The sequences and the concentrations of the oligonucleotides used in the final assay are given in Table 1 .
Preparation of the Biodyne C membrane (Pall BioSupport) was essentially as described by Zang et al. (7 ) . The membrane strips were prehybridized in 3 mL of 2ϫ standard saline citrate, pH 7, containing 1 g/L sodium dodecyl sulfate in a plastic bag at 53°C for 15 min. We denatured 20 L of each multiplex PCR product at 95°C for 10 min, put the denatured products on ice for 5 min, added the hybridization solution, and incubated the products individually with the membrane strips at 53°C for 1 h. After hybridization, the strips were washed with 5 mL of fresh hybridization solution at 53°C for 10 min. After washing, strips were incubated with 5 mL of fresh hybridization solution containing 3 units of streptavidinalkaline phosphatase conjugate at room temperature for 30 min. Excess conjugate was removed with two 5-min washes in 0.1 mol/L diethanolamine, pH 10, containing 1 mmol/L MgCl 2 and 0.1 g/L sodium azide. The strips were then incubated in the dark with 0.1 mol/L Tris, pH 9.5, containing 0.1 mol/L NaCl, 50 mmol/L MgCl 2 , 0.6 mg of nitroblue tetrazolium, and 0.3 mg of 5-bromo-4-chloro-3-indolyl phosphate for 30 min, after which the strips were blocked with a 5 mL of 20 mmol/L Tris, pH 7.5, containing 5 mmol/L EDTA.
In this study, exploiting the allelic homogeneity of WD in this population, we developed a RDB system that simplifies mutation screening because by screening for only the six most common mutations, we cover 85% of the total number of WD chromosomes.
Using the RDB method and SSCP analysis, we analyzed 63 individuals referred to our center for molecular analysis of WD. The obtained results agreed with both the RDB and the SSCP methods of analysis (our unpublished data). In our hands, the RDB assay is a rapid, sensitive, and easy system for screening multiple mutations in a single assay and allows testing for the majority of WD defects (85%) in this population. Another advantage of the RDB assay is that one patient can be screened with only one strip. This minimizes sample confusion in all of the steps. On the basis of these data, we can conclude that the most efficient strategy in the molecular diagnosis of WD in the Sardinian population is a first-step mutation screening for the six most common mutations with multiplex PCR followed by RDB analysis. Samples not characterized with this first step will be subsequently characterized by SSCP analysis of all of the exons and the promoter region of the ATP7B gene. 
